RxDoctor Payments Data

Carolyn Moore, NP

Family · Atlanta, GANPI 1114161791

Payments from drug & device makers

$943in general payments, 2019–2025

Across 26 payments — averaging $36.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$449
  • Edwards Lifesciences$144
  • Boehringer Ingelheim$117
  • Novartis$65
  • E.r. Squibb & Sons, L.L.C.$46
  • AstraZeneca$34
  • plus $88 from 4 others

What the payments were for

  • Food & beverage$943100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$943 in reported general payments places this provider in the 65th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$53,274
Medicare patients
195
Services billed
799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan124$140,396
JardianceEmpagliflozin89$92,890
FarxigaDapagliflozin Propanediol71$64,937
Isosorbide Dinitrate23$1,734
Metoprolol Succinate93$1,557
Spironolactone155$1,174
Eplerenone15$606
Carvedilol72$573
Torsemide39$565
Losartan Potassium33$361
Hydralazine Hcl38$343
Furosemide59$233
Lisinopril15$114
Amlodipine Besylate12$28

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$65$140,396124 claims
Boehringer IngelheimJardiance$117$92,89089 claims
AstraZenecaFarxiga$34$64,93771 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,258 family providers in Georgia.

Other family in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →